Rasagiline - Is there a place for this drug in managing Parkinson's disease?

International Journal of Clinical Practice

Volumn 60, Issue 2, 2006, Pages 132-133

  Sharma, Jagdish C ^a  

^a SHERWOOD FOREST HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2 RECEPTOR ANTAGONIST; AMPHETAMINE; ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG METABOLITE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; NEUROPROTECTIVE AGENT; RASAGILINE; SELEGILINE;

APOPTOSIS; DOPAMINERGIC TRANSMISSION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG SAFETY; DYSKINESIA; EDITORIAL; HUMAN; IN VITRO STUDY; NEUROIMAGING; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; SYMPTOMATOLOGY;

HUMANS; INDANS; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 33646710098     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.00843d.x     Document Type: Editorial

References (10)

1. Stocchi F. Rasagiline: Defining the role of a novel therapy in the treatment of Parkinson's disease. Int J Clin Pract; 60: 215-221.
2. Whone AL, Watts RL, Stoessl AJ et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54: 93-101.
3. CALM-PD and CALM-PD Parkinson Study group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson's disease progression. JAMA 2002; 287: 1653-61.
4. Clarke CE. A 'Cure' for Parkinson's disease: Can neuroprotection be proven with current trial designs? Mov Disord 2004; 19: 491-8.
5. Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A on behalf of the ComQol Study Group. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing off type fluctuations. Acta Neurol Scand 2005; 111: 21-8.
6. Olanow CW, Agid Y, Mizuno Y et al. Levodopa in the treatment of Parkinson's disease: Current controversies. Mov Disord 2004; 19: 997-1005.
7. Rascol O, Brookes DJ, Korczyn AD et al. A five year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342: 1484-91.
8. Sharma J, Macnamara L, Vassallo M. Levodopa associated dyskinesia in Parkinson's disease is related to body weight. Age Ageing 2005; 1 (Suppl. 1): I31 (Abstract).
9. Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE. Monoamine oxidase typeB inhibitors in early Parkinson's disease: Meta-analysis of 17 randomised trials involving 3525 patients. BMJ 2004; 329: 593-6.
10. Ben-Shlomo Y, Bhatia K. Using monoamine oxidase type B inhibitors in Parkinson,s disease. BMJ 2004; 329: 581-2.